15 Oct 2025
15th of October 2025
Brussels, October 15th, 2025
NEAT ID e-poster presentation at EACS 2025: Results from the “DREW” Study.
New European Data Support Doravirine Use in People Living with HIV and NNRTI Resistance: NEAT ID Poster Presented at EACS 2025
Results from a European study presented as an e-poster at the 20th European AIDS Conference (EACS 2025, Paris) offers encouraging real-world evidence supporting the use of Doravirine (DOR)-based regimens in people living with HIV (PLWH) who carry non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance-associated mutations (RAMs) - if genotypic susceptibility to DOR is preserved. This is the first study to evaluate DOR efficacy in this patient population across multiple real-world clinical settings.
This retrospective observational study was conducted across 14 clinical sites in 5 European countries - the United Kingdom, France, Spain, Belgium, and the Netherlands - between February and May 2025. It evaluated virological outcomes in 58 PLWH who had documented NNRTI RAMs but no predicted high or intermediate-level resistance to DOR, and who had initiated a DOR-containing regimen, either as first-line therapy or as a switch strategy.
Of the 58 participants, 56 were treatment-experienced, and 2 were treatment-naïve. At baseline, all treatment-experienced individuals had an undetectable viral load. The study population was diverse, with a median age of 50 years, and 69% of participants identified as male. Most patients received a regimen combining DOR with tenofovir disoproxil fumarate and lamivudine (TDF/3TC), while a smaller proportion received DOR with tenofovir alafenamide and emtricitabine (TAF/FTC).
The most common NNRTI RAMs observed were E138A/K (41.4%), V179I (27.6%), K103N/S (19%), V90I (12.1%), and A98S (10.3%). Notably, three treatment-experienced patients had baseline low-level genotypic resistance to DOR, and three had nucleoside reverse transcriptase inhibitor (NRTI) RAMs.
At 48 weeks, virological success - defined as HIV RNA <50 copies/mL by the FDA Snapshot algorithm - was achieved in 100% of treatment-naïve participants and 92.9% of treatment-experienced participants (95% confidence interval: 82.7–98.0). No participants were lost to follow-up or discontinued DOR during the study period. Only one case of virological failure was reported, in a treatment-experienced individual with multiple baseline NRTI and NNRTI mutations, which may have collectively compromised DOR efficacy.
According to the investigators, this is the first European real-world cohort study to demonstrate that DOR-based regimens can maintain high virological efficacy and excellent treatment retention in PLWH with historical NNRTI resistance, provided that genotypic susceptibility to DOR is preserved.
Chief Investigator, Professor Anton Pozniak, noted “"In this large European cohort with NNRTI mutations but preserved genotypic susceptibility to doravirine, doravirine-based regimens were well tolerated and showed excellent efficacy.
Contributing sites: Chelsea and Westminster (UK), Guys Hospital (UK), St Antoine (France), Hospital Bichat (France), Hospital Pitié Salpêtrière (France), St Louis Hospital (France), Mortimer Market (UK), Institute of Tropical Medicine Antwerp (Belgium), Hospital Clinic Barcelona (Spain), CHU Nice (France), CHU Nantes (France), Erasmus Medical Center (Netherlands), Lariboisière Hospital (France), CHU de Montpellier (France)
This study is sponsored by NEAT ID and funded by MSD.
Notes to editors:
1. NEAT ID's mission is to support and develop Clinical Research on Infectious Diseases and spread expertise, resources and funds. NEAT ID provides training and mobility of scientists at all levels and foster lasting research collaborations Internationally. Please visit our website for more details: https://www.NEAT-ID.org
2. Professor Anton Pozniak is a consultant physician in HIV Medicine at the Chelsea and Westminster Hospital, Professor in the Department of Clinical Research at the London School of Hygiene & Tropical Medicine, Past President of the International AIDS Society and NEAT ID. Anton has been an advisor on HIV and AIDS to the UK Government Health Select Committee and a member of the expert advisory group on AIDS for the UK Department of Health. He has published more than 400 peer-reviewed papers, mainly on clinical aspects of HIV treatment and care and HIV-associated tuberculosis.
Media contact: Polly.Parks@NEAT-ID.org +44 07850 695261